The Food and Drug Administration (FDA) has granted a compassionate special permit for the anti-COVID-19 treatment drug Bexovid from Biocare Lifesciences Inc (BLI).
This is the first generic version of Pfizer’s Paxlovid.
According to FDA officer in charge (OIC) Dr. Oscar Gutierrez, the agency approved the application of the Department of Health (DOH) for institutional use of the said cheaper anti-viral pill.
The Bexovid can be used for those who have COVID-19 ages 12 and up with mild to moderate cases of the virus.
According to the study conducted by Pfizer, the pill can reduce the threat of being hospitalized and even death at 88-89% if administered within 3-5 days.
Gutierrez added that the medicine can be accessed and distributed by the DOH and the government hospitals once the supply came from Biocare Lifescience, Inc. has arrived.
Formerly the approval of the usage of the anti-viral pill Paxlovid, which consists of nirmatrelvir and ritonavir, in the United States.
The FDA is expecting that Pfizer will submit an application for its emergency use authorization in the following months.
